Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PEN-866 by Tarveda Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
PEN-866 is under clinical development by Tarveda Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
PEN-866 by Tarveda Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval
PEN-866 is under clinical development by Tarveda Therapeutics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
PEN-866 by Tarveda Therapeutics for Gastric Cancer: Likelihood of Approval
PEN-866 is under clinical development by Tarveda Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
PEN-866 by Tarveda Therapeutics for Colorectal Cancer: Likelihood of Approval
PEN-866 is under clinical development by Tarveda Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
PEN-866 by Tarveda Therapeutics for Ovarian Cancer: Likelihood of Approval
PEN-866 is under clinical development by Tarveda Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...